Tim Wilsdon moderates the session discussing how to fast-track policy solutions that could address the barriers preventing patient access to NGS and identify the ones that should be prioritized.
For more information on this event, click here.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Tim Wilsdon moderates the session discussing how to fast-track policy solutions that could address the barriers preventing patient access to NGS and identify the ones that should be prioritized.
For more information on this event, click here.
Direct oral anticoagulants (DOACs) are widely used pharmaceutical products which represent a significant cost to the healthcare system. In 2021, National...
CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified...